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Abstract:  
Benefits on cognition from docosahexaenoic acid (DHA, 22:6 n-3) intake are absent in 
humans carrying apolipoprotein E ε4 allele (APOE4), the most important genetic risk 
factor for Alzheimer’s Disease (AD). To test the hypothesis that carrying APOE4 impairs 
DHA distribution, we evaluated plasma and brain fatty acid profiles and uptake of [14C]-
DHA using in situ cerebral perfusion through the blood-brain barrier in 4 and 13-month-
old male and female APOE-targeted replacement mice (APOE2, APOE3 and APOE4), 
fed with a DHA-depleted diet. Cortical and plasma DHA were 9% lower and 34% higher 
in APOE4 compared to APOE2 mice, respectively. Brain uptake of [14C]-DHA was 24% 
lower in APOE4 versus APOE2 mice. A significant relationship was established 
between DHA and apoE concentrations in the cortex of mice (r2 = 0.21) and AD patients 
(r2 = 0.32). Altogether, our results suggest that lower brain uptake of DHA in APOE4 
than in APOE2 mice may limit the accumulation of DHA in cerebral tissues. These data 
provide a mechanistic explanation for the lack of benefit of DHA in APOE4 carriers on 
cognitive function and the risk of AD. 
Key words: apolipoprotein E, docosahexaenoic acid, blood brain barrier, long chain 
omega-3 polyunsaturated fatty acids, Alzheimer. 
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Introduction 
Expression of the ε4 allele of apolipoprotein E (APOE) is associated with an increased 
risk for late onset familial as well as sporadic Alzheimer’s disease (AD) (Corder et al., 
1993; Saunders et al., 1993; Strittmatter et al., 1993). The APOE gene has three major 
isoforms in humans, namely apoE2, apoE3 and apoE4. ApoE4 contains two arginine 
residues at position 112 and 158, instead of an arginine and a cysteine in apoE3 and a 
cysteine at both positions for apoE2 (Weisgraber et al., 1981). The frequency for 
APOE4 allele is 13.6% in the general Caucasian population and reaches 36.7% in AD 
patients (Farrer et al., 1997). There is epidemiological evidence supporting lower risk of 
developing AD in APOE2 carriers but higher risk in APOE4 carriers (Corder et al., 1994; 
Hyman et al., 1996; Berlau et al., 2009; Small et al., 2004). Moreover, carrying two 
APOE4 alleles increases the risk of developing AD by nearly fifteen times, compared to 
APOE3 (Farrer et al., 1997; Holtzman et al., 2012). Magnetic resonance imaging shows 
that APOE4 carriage accelerates the rate of hippocampal volume loss in non-demented 
older adults (Jak et al., 2007). Importantly, the alteration of apoE function caused by the 
APOE4 allele has been consistently associated with a reduction of total brain apoE 
concentrations (Bales et al., 1997, Beffert et al., 1999). 
ApoE protein transports cholesterol within the CNS and thus has an important role in 
brain lipid homeostasis (Boyles et al., 1989; Hauser et al., 2011). During aging, the 
brain loses approximately 20% of its weight, mainly in the form of lipids (Svennerholm et 
al., 1997). Among key brain lipids, long chain n-3 polyunsaturated fatty acids (PUFA), in 
particular docosahexaenoic acid (DHA, 22:6 n-3), are enriched in cerebral tissues. Most 
mammals must obtain preformed DHA from their diet because of their limited capacity 
to synthesize DHA from short chain n-3 PUFA (Plourde and Cunnane, 2007). The 
importance of maintaining high DHA concentrations for optimal brain function has been 
highlighted by series of studies in animals (Calon et al., 2004; Hooijmans et al., 2009; 
Arsenault et al., 2011) and clinical trials (Yurko-Mauro et al., 2010). For instance, 
decreasing brain DHA has been shown to be deleterious on synaptic function, 
processing of amyloid precursor protein, and brain glucose uptake (Bowen and 
Clandinin, 2002; Calon et al., 2004; Lim et al., 2005; Pifferi et al., 2005; Holguin et al., 
2008; Arsenault et al., 2011), all of which have been demonstrated to be modulated by 
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APOE genotype (Reiman et al., 2004; Wang et al., 2005; Reiman et al., 2009; Klein et 
al., 2010; Arold et al., 2012; Hashimoto et al., 2012; Koffie et al., 2012; Li et al., 2012; 
Sen et al., 2012; Youmans et al., 2012; Zhu et al., 2012). Therefore, speculating that 
APOE4-induced depletion in DHA may underlie some of its known detrimental effects in 
the aging brain becomes a plausible hypothesis that needs further attention.  
Most of the data from epidemiological and animal studies converge to suggest that diets 
enriched in n-3 PUFA, such as DHA, may protect against AD (Morris et al., 2003; Calon 
et al., 2004; Cunnane et al., 2009; Arsenault et al., 2011; Barberger-Gateau et al., 
2011), although other studies do not support such an association (Devore et al., 2009; 
Engelhart et al., 2002; Mazereeuw et al., 2012). However, when detected, the 
association between n-3 PUFA consumption and lower incidence of cognitive decline is 
lost in APOE4 carriers (Huang et al., 2005; Samieri et al., 2011). Large randomized 
controlled trial (RCT) performed in AD patients consuming 1.7-2.0 g per day of DHA 
found no improvement in cognition after 12-18 months (Freund-Levi et al., 2006, Quinn 
et al., 2010). However, after stratification of the study population by APOE4 genotype, 
non-carriers of APOE4 did improve their cognitive scores on Alzheimer Disease 
Assessment Scale-Cognitive and Mini–Mental State Examination after DHA treatment 
(Quinn et al., 2010). Sub-optimal n-3 PUFA bioavailability in APOE4 carriers is a 
possible explanation since 1) postprandial DHA β-oxidation is higher (Chouinard-
Watkins et al., 2013), 2) whole body half-life of DHA is 77% lower (Chouinard-Watkins 
et al., 2013), 3) plasma DHA increase in response to fish oil supplementation (3 g/day 
for 6 weeks) is 165% lower in APOE4 carriers compared to non-carriers (Plourde et al., 
2009) and 4) unlike APOE2 and APOE3 carriers, n-3 PUFA concentrations in 
erythrocytes are not correlated with better cognitive scores in both young (11-y-old) and 
older participants (65-y-old) expressing the APOE4 allele (Whalley et al., 2008). Taken 
together, these results suggest that APOE4 individuals might benefit less from dietary n-
3 PUFA intake, possibly due to limited bioavailability in target tissue.  
To determine whether the APOE genotype disrupts the accumulation of n-3 PUFA in the 
brain, we used human APOE2, 3 and 4 isoform-specific transgenic mice lacking a 
functional mouse apoE protein. First, we compared plasma and brain fatty acid profiles 
in mice in relation to expression of human APOE2, 3 or 4 in animals of 4 and 13 months 
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of age. To further investigate whether APOE genotype lowers uptake of DHA through 
the blood-brain barrier (BBB) into the brain, we performed in situ brain perfusion of 
[14C]-DHA comparing APOE2, 3 and 4 mice at the same ages. Finally, we confirmed the 
association between DHA relative content and apoE concentrations using cortex 
samples from AD patients and control subjects.  
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Materials and methods  
Animals 
Male and female APOE-targeted replacement mice (APOE2, 3 and 4) and C57BL6 
littermate mice were used for the study (Sullivan et al., 1997). Those mice were created 
by gene targeting and replacing mouse APOE with human APOE2, 3 or 4. APOE and 
C57BL6 control mice were purchased from Taconic (Hudson, NY, USA) and then 
reproduced at our animal facilities to complete the experimental groups. Animals were 
either sacrificed at the age of 4.1 ± 0.5 months (young mice) or at 13.4 ± 1.2 months 
(middle-aged mice). Before the age of 4 months, animals were fed with a commercial 
chow diet (Teklad 2018, Harlan Laboratories, Indianapolis, IN). From 4 to 13 months, 
animals were fed with a low n-3 PUFA, high n-6 PUFA diet (20.3% w/w carbohydrate, 
66% w/w protein and 3.9 kcal/g), as described previously (Bousquet et al., 2011) and 
detailed in Supplementary Table 1. The final pelleted diet was produced by Research 
Diets Inc. (D04042202, New Brunswick, NJ, USA) using a formula precisely determined 
to avoid any batch to batch variations. The low n-3 PUFA, high n-6 PUFA diet was 
chosen to mimic the n-3 PUFA-deprived dietary environment of modern American 
society (Layé, 2010) and to avoid potential confounding long-term effects of circulating 
DHA (Ouellet et al., 2009). The diet started at 4 months of age to avoid 
neurodevelopmental artifacts. At the end of the experimental time, mice were perfused 
in the heart after deep anesthesia with ketamine/xylazine for collecting organs and 
tissues for Western immunoblotting and fatty acid profile determination, or were 
submitted to in situ cerebral perfusion (see below). After sacrifice, the brain was rapidly 
removed and the parieto-temporal cortex was dissected, frozen, powderized and kept at 
-80°C until lipid extraction and Western blot. All experiments were performed in 
accordance with the Canadian Council on Animal Care and were approved by the 
Institutional Committee of the Centre Hospitalier de l’Université Laval (CHUL). 
Patients and handling of brain tissue 
Brain samples from AD patients were obtained from the Douglas Hospital Research 
Center Brain Bank (Montreal, Canada) and were previously described (Julien et al., 
2009). Written informed consent was obtained from all participants or their family for 
collecting brain samples after death. The diagnosis of AD was based on the 
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neuropathologic examination and was classified into definite AD or probable AD 
according to the Consortium to Establish a Registry for AD (CERAD 1/2) diagnostic 
criteria; controls were rated as possible AD or no AD (CERAD 3/4) (Mirra et al., 1994). 
Brain and plasma fatty acid profile 
For mouse samples, total lipids were extracted from ~30 mg parieto-temporal cortex or 
0.5 ml plasma samples by the method described by Folch et al. (Folch et al., 1957). 
Total lipids were saponified and then transmethylated using 14% methanolic boron 
trifluoride. Fatty acid profiles were determined by gas chromatography equipped with a 
flame ionization detector (model 6890, Agilent, Palo Alto, CA, USA) and a 50-m BPX-70 
fused capillary column (SGE, Melbourne, Australia; 0.25 mm inner diameter, 0.25 μm 
film thickness) as previously described (Plourde et al., 2009). For human brain samples, 
details on the methodology for fatty acid profile determination are reported elsewhere 
(Julien et al., 2009).  
In situ cerebral perfusion 
In situ cerebral perfusion technique was performed as previously described (Dagenais 
et al., 2000; Ouellet et al., 2009). This method allows the quantification of the transport 
of labeled molecules such as fatty acids through the BBB (Ouellet et al., 2009) and is 
performed by rigorously controlling perfusate composition, flow and volume, in the 
absence of peripheral metabolism (Dagenais et al., 2000). Briefly, after being 
anesthetized with a mixture of ketamine and xylazine (140/8 mg/kg), the right common 
carotid artery was catheterized after a ligation of the external branch. Then, the thorax 
was opened, the heart was removed and the perfusion started. The perfusion solution 
(bicarbonate buffered physiological saline, 128 mM NaCl, 24 mM NaHCO3, 4.2 mM KCl, 
2.4 mM NaH2PO4, 1.5 mM CaCl2, 0.9 mM MgCl2 and 9 mM D-glucose) was gassed with 
95% O2 and 5% CO2 to reach a pH of 7.4 and then kept at 37°C. The perfusion flow rate 
was set at 1.68 ml/min for a total of 60 seconds after which the animal was decapitated. 
[14C]-DHA (0.3 µCi/ml, 5 µM, Moravek Biochemicals, Brea, CA, USA) radiolabeled 
tracer was used to assess DHA transfer across the BBB. To quantify the vascular 
volume, [14C]-sucrose (0.3 µci/ml) was perfused to another set of mice. After the 
perfusion, the brain was removed, the right hemisphere was digested in 1 ml of 
Solvable (Perkin-Elmer Life Sciences, Boston, MA, USA) overnight at 50°C. Nine ml of 
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HighSafe scintillation cocktail (Perkin-Elmer Life Sciences, Boston, MA, USA) was 
added to the samples. A Wallac scintillation counter (Perkin-Elmer Life Sciences, 
Boston, MA, USA) was used to quantify 14C in the digested brain hemisphere. The 
volume of distribution (VD) of [
14C]-DHA was expressed in μl/g and was calculated by 
dividing the concentration of [14C]-DHA in the brain (µCi/g) with the concentration of 
[14C]-DHA in the perfusate (µCi/μl). The volume of distribution (VD) of [
14C]-DHA was 
corrected by subtracting the vascular space (Vvasc) also expressed in μl/g and 
determined by co-perfusing [3H]-inulin (0.3 µCi/ml). The brain [14C]-DHA transport 
coefficient (Clup; ml g-1s-1) was calculated by dividing the corrected apparent volume of 
distribution of [14C]-DHA with the perfusion duration. 
Western immunoblotting 
Mouse parieto-temporal cortex and human parietal cortex were homogenized in 8 
volumes and 5 volumes, respectively, of TBS solution containing a cocktail of proteases 
inhibitor (CompleteTM, Roche Diagnostics, Indianapolis, IN, USA) and phosphatases 
inhibitor (Phostop (Roche Diagnostics, Indianapolis, IN, USA), sodium orthovanadate 
and sodium fluoride). Samples were sonicated and centrifuged at 100,000 g for 20 min 
at 4°C to generate a homogenate containing TBS-soluble proteins. Protein 
concentration of the resulting TBS-soluble supernatant was assessed by Bicinchoninic 
Acid Protein Assay Kit (Pierce, Rockford, IL, USA). Twenty μg of proteins were loaded 
and separated by sodium dodecyl sulfate-polyacrylamide electrophoresis gel and then 
electroblotted onto a PVDF membrane (Immobilon, Millipore, MA, USA). Membranes 
were blocked in 5% milk with 0.5% bovine serum albumin for 1 hour and immunoblotted 
with primary and then secondary antibodies followed by chemiluminescence reagents 
(LumiGLO Reserve Chemiluminescent Substrate Kit, KPL, Gaithersburg, MD, USA). 
Band intensities were determined using a KODAK Image Station 4000 MM (Molecular 
Imaging software version 4.0.5f7, KODAK, New Havem, CT, USA) Human apoE 
(1:20000, Novus Biological, Littleton, CO, USA), mouse apoE (1:2000, Novus 
Biological, Littleton, CO, USA) and actin (1:10000, Applied Biological Materials, 
Richmond, BC, Canada) antibody were used as primary antibody. 
Statistical analysis 
Data are presented as the Mean ± SEM. As no statistical difference has been found 
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between males and females, both gender were combined in each graph to enhance the 
statistical power. To achieve a probability higher than 90% of not committing a Type II 
error (power analysis), with expected changes of cortical DHA concentrations and brain 
DHA uptake estimated at 20%, a standard deviation of 20% and an α value set at 0.05, 
the number of mice per group was thus set at 10. For the human study, the magnitude 
of change in the measured endpoints was estimated at 20% according to published 
data (Bertrand et al., 1995). With an estimated standard deviation of 40% for Western 
Blot, and α set at 0.05, the number of human participants required per group was 20 to 
achieve 88% power.  APOE2, APOE3 and APOE4 mice were compared by performing 
one-way ANOVA followed by Tukey-Kramer post hoc test and correlations were done 
using Pearson’s correlation. No statistical comparison was made between young and 
middle-aged APOE mice because experiments were done separately. The number of 
mice per group is specified in each graph. Statistical significance was set at p<0.05. All 
statistical analyses were performed with Prism 4 (GraphPad software, San Diego, CA, 
USA) software. 
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Results  
APOE4 genotype was associated to a lower cortex DHA relative content 
Fatty acid profiles were first determined in samples from the parieto-temporal cortex to 
assess whether the APOE4 genotype was associated with lower relative levels of brain 
DHA. In the young group of mice, the arachidonic acid (ARA; 20:4 n-6) percentage was 
6% higher in APOE3 cortex than APOE2 mice of the same age (Fig. 1A. p<0.05). In 
separate experiments performed in 13-month-old mice, we noticed a higher proportion 
of n-6 docosapentaenoic acid (n-6 DPA, 22:5 n-6) in APOE3 mice (Fig. 1B. +10%, 
p<0.05) compared to APOE2 mice. Interestingly, among PUFAs, DHA was particularly 
sensitive to APOE4 genotype since DHA proportion was 9% lower in 13-month-old 
APOE4 mice compared to APOE2 mice of the same age (Fig. 1B.). 
APOE genotype modulates plasma fatty acid profile in young and old mice 
N-6 and n-3 PUFA plasma composition was similar between groups in young mice (Fig. 
2A.); however, significant changes were detected in 13-month-old mice. The relative 
content of total n-6 PUFA was 15% higher in APOE4 mice compared to other genotypes 
(p<0.05) whereas total n-3 PUFA were nearly 40% higher in both APOE3 and APOE4 
mice (Fig. 2B. p<0.05) compared to APOE2 mice. More specifically, APOE3 and 
APOE4 expression led to 64% and 77% higher percentage of ARA in plasma total lipids 
compared to APOE2 mice, respectively (Fig. 2B.). In addition, 13-month-old APOE4 
mice had 34% higher plasma DHA than APOE2 mice (Fig. 2B. p<0.05).  
Reduced brain DHA uptake in APOE4 mice 
The cerebrovascular volume and physical integrity of the BBB was assessed by 
perfusing the vascular space markers [14C]-sucrose or [3H]-inulin, which have a very 
poor BBB permeability under normal conditions. No difference of vascular volume was 
detected (Fig. 3A. and 3B.), suggesting that no major BBB leakage occurred during the 
experiments and ruling out the presence of a major cerebrovascular anomaly in APOE4 
mice. The Clup for [14C]-DHA was 18% lower in 4-month-old (p<0.05) and 24% lower in 
13-month-old (p<0.01) APOE4 mice (Fig. 3A. and 3B. p<0.05 and p<0.01), compared to 
the APOE2 mice, indicating that the brain transport of [14C]-DHA across the BBB was 
reduced by APOE4 expression in mice.  
Reduced cortex human apoE content in APOE4 mice. 
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As previously found in the same model (Riddell et al., 2008; Sullivan et al., 2011), the 
concentrations of human apoE was 56% and 43% lower in APOE4 compared to APOE2 
mice at 4 and 13 months of age (Fig. 4A. 1) p<0.001 and 2) p<0.05, respectively). There 
was a significant difference in the TBS-soluble fraction and a similar trend was found in 
detergent-soluble fraction (Supplementary Fig. 2). These results differ from data 
previously published by Youmans et al., showing a reduction in apoE concentration in 
APOE4 mice but only in detergent-soluble fractions (Youmans et al., 2012). In addition, 
we found that brain [14C]-DHA uptake correlated with cortical apoE concentrations in 
young animals (Fig. 4B. 1) r2 = 0.34, p<0.01) and with the percentage of DHA in cortical 
fatty acids from young and older animals (Fig. 4C. 1) r2 = 0.21, p<0.01 and 2) r2 = 0.15, 
p<0.01, respectively).  
Cortex DHA correlated with apoE concentration in AD patients. 
In line with previous studies, post mortem concentrations of apoE in the parietal cortex 
from AD patients were 61% lower compared to control donors (Fig. 5A. p<0.01) 
(Bertrand et al., 1995; Beffert et al., 1999). In addition, cortical concentrations of apoE 
were correlated with cortex DHA composition in AD patients (Fig. 5B. r2 = 0.32, p<0.01) 
but not in control subjects (Fig. 5B. r2 = 0.003, p = 0.81).  
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Discussion  
The present study shows that plasma and brain fatty acid profiles as well as DHA 
transport across the BBB are influenced by human APOE genotype. Expression of 
human APOE4 led to a lower proportion of DHA among brain fatty acids when 
compared to APOE2 mice. The in situ demonstration of a significantly lower transfer of 
DHA across the BBB in APOE4 mice suggests that impaired uptake mechanisms of 
DHA may have led to lower brain DHA over time. Most of the significant differences 
highlighted by this study were found between APOE2 and APOE4 mice whereas almost 
no difference was observed between APOE3 and APOE4 mice. Therefore, our results 
could be equally attributed to a protective effect of APOE2 than to a deleterious effect of 
APOE4, in line with the meta-analysis of multiple epidemiological studies yielding AD 
risk odds ratio of 3.68 and 0.62 for APOE4 and APOE2, respectively, compared to 
APOE3 carriers (www.alzgene.org).  
Lower brain uptake of DHA in APOE4 compared to APOE2 mice : possible 
mechanisms and consequences. 
One of the most striking observations reported here is the effect of APOE genotype on 
brain of uptake of [14C]-DHA. As evidenced by in situ cerebral perfusion, expression of 
APOE4 led to a lower brain DHA uptake compared to APOE3 and APOE2 genotype in 
4-month-old mice, but only compared to APOE2 mice at 13 month. Limited diffusion of 
DHA in the brain can obviously have important long-term consequences. However, to 
understand how apoE influences brain DHA transport, one must first know how blood-
borne DHA normally accesses the brain. Unfortunately, mechanisms by which DHA is 
transported through the BBB in the brain parenchyma are subject to controversies. It 
has been shown experimentally that free unbound DHA readily crosses the BBB 
through simple non-saturable diffusion (Hamilton and Brunaldi, 2007; Ouellet et al., 
2009). Albeit in low concentrations at equilibrium, it is expected that enough free 
unbound DHA is available for the brain at any time to ensure supply to the brain 
(Hamilton and Brunaldi, 2007; Ouellet et al., 2009). Supporting this view, post-mortem 
plasma and brain DHA concentrations correlate well in animal models (Huang et al., 
2007; Tu et al., 2012) and humans (Cunnane et al., 2012). On the other hand, other 
reports suggest that the exact plasma component to which DHA is bound can influence 
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its brain uptake or that fatty acid transporters may regulate DHA transport across 
endothelial cell membranes (Edmond, 2001; Mitchel and Hatch, 2011). Data gathered 
after intravenous injections of radiolabeled lipids suggests that DHA transport through 
the BBB is enhanced after binding to certain type of lipoproteins (Lagarde et al., 2001; 
Polozova and Salem, 2007), supporting a lipoprotein-mediated DHA transport to the 
brain. Despite the limited knowledge available about DHA transport across the BBB, 
several lines of thoughts can still be proposed to explain how apoE altered brain DHA 
uptake. First, if binding of DHA to transporters or lipoproteins is involved, then changes 
in apoE conformation modifying its binding properties would limit or enhance DHA 
transport to organs. As an example, changes in the interaction between the apoE-DHA 
complex and its receptors located at the BBB may therefore enhance or lower DHA 
transport through the BBB. One BBB receptor for which apoE affinity is known to differ 
between isoforms (APOE4 and APOE3 > APOE2) is the Low Density Lipoprotein 
receptor (LDL-R) (Malhey et al. 2009; Weisgraber et al., 1982). Secondly, the lower 
concentration of the apoE protein in the plasma of APOE4 mice and humans (Fitz et al., 
2012; Yasuno et al., 2012, Riddell et al., 2008) might result in less binding sites 
between lipoproteins and receptors, thereby reducing brain DHA uptake. On the other 
hand, however, results from the present in situ experiments, performed with a buffer 
devoid of circulating lipoproteins, strongly argue for a direct long-term effect of apoE on 
BBB function. The fact that DHA can cross the BBB by simple diffusion does not rule 
out the importance of regulatory mechanisms.  Indeed, we have previously shown that 
chronic n-3 PUFA deprivation reduces DHA uptake into the brain, arguing that BBB 
permeability of DHA depend on brain needs (Ouellet et al., 2009). Such a view is also in 
agreement with recent reports on major BBB dysfunction in APOE4 mice (Bell et al., 
2012; Hawkes et al., 2012). Accordingly, the decreased passage of DHA across the 
BBB could results from a reduction of the cerebral vascularization in APOE4 mice, as 
previously demonstrated (Bell et al.; 2012). 
Impaired brain DHA uptake is associated with lower brain DHA concentrations in 
13-month-old APOE4. 
A change in DHA transport would be of limited consequence per se if not translated into 
altered concentrations in cerebral tissue. Replacing the coding sequence of the mouse 
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APOE gene with any of the 3 human APOE coding regions had little consequence for 
cortex fatty acid profiles at 4 month. Only a slightly higher relative level of ARA in young 
APOE3 mice was observed. This finding is consistent with a previous study reporting no 
difference in the relative levels of hippocampal DHA between ~5 month-old APOE3 and 
APOE4 mice (Kariv-Inbal et al., 2012). In contrast, lower DHA relative ratio in 13-month-
old APOE4 mice indicates that long-term term expression of human APOE4 has 
consequences on the brain membrane composition. Lower brain DHA uptake in APOE4 
mice over 13 months of life provides a simple explanation for observing lower cortex 
DHA content at this time point. Yet, the reason why lower brain DHA uptake in 4-month-
old APOE4 mice does not translate into lower cortex DHA content is unclear. Perhaps, it 
is simply because reduced supply of DHA needs to last over several months to translate 
into a significant decrease in brain DHA levels. DHA turnover in the brain is estimated to 
last up to 33 days in mice and 2.5 y in humans (Umhau et al., 2009; Rapoport et al., 
2011). However, brain DHA half-life in APOE4 is likely to be shorter since it was 
recently reported that plasma DHA half-life was 31% lower than in non-carriers 
(Chouinard-Watkins et al., 2013). Therefore, it is possible that DHA is β-oxidized faster 
in older animals (Plourde et al., 2011) leading to impaired capacity to maintain brain 
DHA composition, and failure to compensate the lower transport across the BBB of 
DHA observed in mice expressing APOE4. In support to this interpretation is the loss of 
the correlation between DHA uptake and apoE content in old mice. In any case, these 
data suggest that the effect of APOE genotype on DHA brain uptake is present early, 
whereas its consequence on DHA accumulation is age-dependent. 
Is the rise in plasma DHA in 13-month-old APOE4 mice the result of reduced 
distribution in the brain? 
Old APOE4 mice had relatively higher plasma DHA, a result in line with observations in 
human APOE4 carriers showing higher DHA relative content in plasma triglycerides 
than non-carriers (Plourde et al., 2009). This result might reflect a key role of apoE 
protein in plasma lipid transport from the liver to target tissues, including the brain 
(Mahley and Rall, 2000; Anil, 2007; Hooijmans and Kiliaan, 2008). Indeed, the main 
supply source of DHA for the brain is from the plasma (Diau et al., 2005; Umhau et al., 
2009). On the one hand, the higher plasma composition in DHA observed here in 
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APOE4 compared to APOE2 mice might be explained by an enhanced DHA carrying 
capacity in the blood. However, this should have been associated with increased brain 
DHA concentrations, which was not the case. On the other hand, such plasma data may 
also reflect a failure of DHA transport and distribution in target tissues, including the 
brain. Obviously, the lower relative DHA content found in the brain favors the second 
explanation, which is also supported by in situ perfusion data confirming a lower 
capacity of DHA to cross the BBB in 4-month-old as well as in 13-month-old APOE4 
mice. Therefore, the combination of the data generated here suggests that a lower brain 
DHA uptake in 13-month-old APOE4 mice is associated with an accumulation of DHA in 
the blood and ultimately lower concentrations in cerebral tissue, in comparison to 
APOE2 animals.  
Brain DHA composition is linked to apoE content. 
The data presented hitherto is significant only if representative of what is occurring in 
humans. Since the present experimental paradigm cannot be replicated in human 
volunteers, we performed linear regression analyses on brain samples from AD 
patients. Indeed, a significant post mortem correlation was found between DHA and 
apoE concentrations in the cortex of both transgenic mice and AD patients. This last 
observation in both species is consistent with a dose-dependent role of apoE protein 
content for maintaining brain DHA composition. In line with the assumption that APOE4 
allele on AD pathogenesis is deleterious and might partly be attributed to lower apoE 
tissue concentrations (Farrer et al., 1997, Beffert et al., 1999). The question that now 
has to be investigated is whether giving a high DHA diet can reverse this association 
and restore brain DHA in APOE4 carriers to a level similar to non-carriers. If this 
hypothesis is confirmed, there is a large potential for translational research to the clinic. 
Therefore, the next step would be to determine adequate DHA intake for APOE4 
carriers for preventing cognitive decline. 
In summary, our results indicate that cerebral uptake and homeostasis of DHA is largely 
influenced by the APOE genotype where APOE4 carriers displayed lower brain uptake 
of DHA than non-carriers. Therefore, restoring n-3 PUFA homeostasis by providing a 
DHA-enriched diet should be considered in future trial studying APOE4 carriers, ideally 
before the first symptoms of cognitive decline (Calon 2011). In addition, given the fact 
 
 17
that APOE4 carrier represents 36.7% of AD patients, these results may have important 
nutrigenetic consequences that need to be taken into account in future DHA 
supplementation trials (Barberger-Gateau et al., 2011). Finally, since maintaining 
optimal brain DHA levels is essential for cognitive health, by showing that APOE4 
expression leads to reduced uptake and accumulation of DHA in the brain, our results 
also suggest a possible new mechanism by which APOE4 aggravates the risk of 
developing AD. 
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Figure legends 
Figure 1 : Cerebral cortex fatty acid composition (%) in 4-month-old (A) and 13-month-
old mice (B), according to APOE genotype. Each fatty acid is presented as % 
composition within total fatty acids. Cortex arachidonic acid (1), n-6 docosapentaenoic 
acid (2), n-6 polyunsaturated fatty acids (3) and docosahexaenoic acid (4) were 
analyzed by gas chromatography. Data are presented as mean ± SEM (n = 11 to 20 
mice/group). One-Way ANOVA followed by post hoc Tukey-Kramer test was used to 
compare data. *p<0.05. 
Figure 2 : Plasma fatty acid profile (%) is modulated by APOE genotype in 4-month-old 
(A) and 13-month-old mice (B). Fatty acid composition is presented as % composition 
within total fatty acids. Plasma arachidonic acid (1), total n-6 polyunsaturated fatty acids 
(2), docosahexaenoic acid (3) and total n-3 polyunsaturated fatty acids (4) were 
analyzed by gas chromatography. Data are presented as mean ± SEM (n = 6 to 11 
mice/group). One-Way ANOVA, post hoc Tukey-Kramer was used to compare data. 
*p<0.05; ***p<0.0001. 
Figure 3 : Brain docosahexaenoic acid (DHA, 22:6 n-3) uptake of 4-month-old and 13-
month-old APOE4 mice is lowered. Brain uptake of [14C]-DHA (1) and cerebrovascular 
volume (2) in 4-month-old (A) and 13-month-old (B) mice determined with in situ 
cerebral perfusion technique. Data are presented as mean ± SEM (n = 5 to 9 
mice/group). One-Way ANOVA, post hoc Tukey-Kramer was used to compare data. 
*p<0.05; **p<0.01. 
Figure 4 : Cortex human APOE content (A) correlates with docosahexaenoic acid (DHA, 
22:6 n-3) passage across the blood brain barrier (B) and with % cortex DHA change 
compared to C57BL6 mice (C) in 4-month-old (1) and 13-month-old (2) APOE2, 3 and 4 
mice. TBS-soluble APOE content in cerebral cortex was determined by Western blot. 
Data are presented as mean ± SEM (n = 6 to 18 mice/group). One-Way ANOVA, post 
hoc Tukey-Kramer was used to compare groups. Correlations between variables were 
evaluated using Pearson’s correlation test. *p<0.05; **p<0.01; ***p<0.0001. 
Figure 5 : Brain APOE concentrations correlate with docosahexaenoic acid (DHA, 22:6 
n-3)  relative content in AD patients. APOE concentration in TBS-soluble fraction of the 
parietal cortex samples was measured by Western Blot. Brain DHA is presented as % 
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composition within total fatty acids. Proportion of DHA within brain fatty acids was 
determined by gas chromatography. Data are presented as mean ± SEM (n = 20 to 22 
subject/group). Welch’s unpaired t-test was used to compare groups. Correlations 
between variables were evaluated using Pearson’s correlation test **p<0.01.
 
 
 
 
 2
 
 
 3
 
 
 4
 
 
 5
 
